5-α还原酶的表达与前列腺癌生物学行为相关性研究

doi:10.3969/j.issn.1006-7795.2016.03.010

首都医科大学学报 ›› 2016, Vol. 37 ›› Issue (3): 307-312.doi: 10.3969/j.issn.1006-7795.2016.03.010

• 前列腺癌发病机制与临床治疗研究 • 上一篇下一篇

5-α还原酶的表达与前列腺癌生物学行为相关性研究

孙剑, 靳松, 赵宏颖, 刘洋, 金木兰, 邢念增, 牛亦农

首都医科大学附属北京朝阳医院泌尿外科, 北京 100020

收稿日期:2016-04-06 出版日期:2016-06-21 发布日期:2016-06-13
通讯作者: 牛亦农 E-mail:farmerniu@163.com
基金资助:
北京市自然科学基金(7122074)。

Correlation between 5-α reductase and biological behavior of prostate cancer

Sun Jian, Jin Song, Zhao Hongying, Liu Yang, Jin Mulan, Xing Nianzeng, Niu Yinong

Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China

Received:2016-04-06 Online:2016-06-21 Published:2016-06-13
Supported by:
This study was supported by Natural Science Foundation of Beijing(7122074).

摘要/Abstract

摘要： 目的探讨两型5-α还原酶表达情况与前列腺癌Gleason分级、血清前列腺特异性抗原(prostate specific antigen,PSA)浓度、TNM分期的相关性。方法选取2013至2014年间首都医科大学附属北京朝阳医院病理科前列腺癌的石蜡包埋组织40例,并收集患者基本信息、前列腺体积,术前PSA浓度,术后病理TNM分期,Gleason分级等。采用χ²检验和Spearman相关分析对2种5-α还原酶表达与病理分期、Gleason分级、PSA浓度及年龄等参数的关系进行分析。结果 Ⅰ型5-α还原酶在前列腺癌组织中的表达明显高于癌旁组织(P <0.001),相反Ⅱ型5-α还原酶在癌旁组织的表达强于癌组织(P=0.002),Ⅰ型5-α还原酶在癌细胞中的表达与肿瘤的恶性程度呈正相关,Gleason分级越高,病理分期越高,Ⅰ型5-α还原酶的表达越强;Ⅰ型5-α还原酶表达和血PSA浓度及年龄呈正相关。结论 5-α还原酶在前列腺癌组织中呈现差异性表达的特点,前列腺癌组织内I型酶升高,II型酶降低;I型酶的表达与年龄、PSA浓度、病理分期及Gleason分级呈正相关,在老年人群前列腺癌的发生发展中可能具有重要的作用,I型酶对判断前列腺癌的生物学行为及预后可能具有一定意义。

关键词: 5-α还原酶, Gleason分级, TNM分期, 前列腺特异性抗原, 前列腺癌

Abstract: Objective To investigate the correlation between the expression of two types of 5-αreductase and Gleason score, serum prostate-specific antigen (PSA) concentration, and TNM stage in prostate cancer (PCa). Methods Paraffin-embedded PCa specimens of 40 cases were collected in our hospital from 2013 to 2014. Other data of these patients were also collected including the basic information, prostate volume, preoperative serum PSA concentration, postoperative pathological TNM stage, Gleason score and so on. Chi-square test and Spearman rank correlation were used to analyze the correlation.Results The expression of type I 5-α reductase in PCa tissues was significantly stronger than that in the paraneoplastic tissues (Chi-square test, P <0.001). On the contrary, the expression of type II 5-α reductase in the paraneoplastic tissues was stronger than that in PCa tissues (Chi-square test, P=0.002). expression of type I 5-α reductase in PCa epithelial cells was positively correlated with patient's age, serum PSA, the degree of tumor malignancy, Gleason score, and clinical stage.Conclusion Expression of 5-α reductases in PCa are different, type I enzyme is increased, and type II enzyme is decreased. The expression of type I enzyme is positively correlated with age, serum PSA concentration, pathological stage and Gleason score. These findings suggest that these enzymes may play an important role in the development and progression of prostate cancer in the elderly population. Type I enzyme may have a certain significance in judging the biological behavior and prognosis of prostate cancer.

Key words: 5-α reductase, Gleason score, TNM stage, prostate specific antigen (PSA), prostate cancer

中图分类号:

R737.25

孙剑, 靳松, 赵宏颖, 刘洋, 金木兰, 邢念增, 牛亦农. 5-α还原酶的表达与前列腺癌生物学行为相关性研究[J]. 首都医科大学学报, 2016, 37(3): 307-312.

Sun Jian, Jin Song, Zhao Hongying, Liu Yang, Jin Mulan, Xing Nianzeng, Niu Yinong. Correlation between 5-α reductase and biological behavior of prostate cancer[J]. Journal of Capital Medical University, 2016, 37(3): 307-312.

参考文献

[1] Wu Y, Godoy A, Azzouni F, et al. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5alpha-reductase inhibitors[J]. Prostate, 2013, 73(13): 1470-1482.
[2] Wang K, Fan D D, Jin S, et al. Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications[J]. Asian J Androl, 2014, 16(2): 274-279.
[3] NCCN. The NCCN prostate cancer clinical practice guidelines in oncology (version 2.2016)[EB/OL]. Fort Washington: NCCN,2016[2016-03-13]. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pd
[4] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1): 11-30.
[5] 樊东东,王凯,靳松,等. 5-α还原酶在人前列腺组织中的差异性表达及其抑制剂治疗前列腺疾病的临床应用[J]. 中华泌尿外科杂志,2015, 36(1): 75-78.
[6] Godoy A, Kawinski E, Li Y, et al. 5alpha-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression[J]. Prostate, 2011, 71(10): 1033-1046.
[7] Thomas L N, Douglas R C, Lazier C B, et al. Type 1 and Type 2 5α-reductase expression in the development and progression of prostate cancer[J]. Eur Urol, 2008, 53(2): 244-252.
[8] Silver R I, Wiley E L, Davis D L, et al. Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease[J]. J Urol, 1994, 152(2 Pt 1): 433-437.
[9] Das K, Lorena P D, Ng L K, et al.Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer[J]. Endocr Relat Cancer,2010, 17(3): 757-770.
[10] Ge R, Wang Z, Bechis S K, et al. DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate[J]. Am J Pathol, 2015, 185(3): 870-882.
[11] Niu Y, Ge R, Hu L, et al. Reduced levels of 5-α reductase 2 in adult prostate tissue and implications for BPH therapy[J]. Prostate, 2011,71(12):1317-1324.
[12] Uysal F, Akkoyunlu G, Ozturk S. Dynamic expression of DNA methyltransferases (DNMTs) in oocytes and early embryos[J]. Biochimie, 2015, 116: 103-113.
[13] Titus M A, Gregory C W, Ford O H 3rd, et al. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer[J]. Clin Cancer Res, 2005, 11(12): 4365-4371.
[14] 秦桂萍,华玉兰,侯海娜. 前列腺癌组织p504S和p63与血清PSA表达水平相关性分析[J]. 中华肿瘤防治杂志, 2013,20(3):200-202.
[15] 杜雄,惠起源,尹香利,等. PSA、CgA及PCA3在前列腺癌中的表达及临床意义[J]. 解放军医药杂志,2014,26(2):47-49.
[16] 王炜,李传刚,刘辉,等. 前列腺特异性抗原对前列腺癌诊断价值的探讨[J]. 中国医科大学学报, 2016,45(1):61-65,69.
[17] Loeb S, Catalona W J. Prostate-specific antigen in clinical practice[J]. Cancer Lett, 2007, 249(1): 30-39.
[18] 刘贺亮,王禾,杨晓剑,等. 血清PSA、FPSAR与前列腺癌病理分级、临床分期的相关性研究[J]. 中华男科学, 2002,8(4): 261-263.

5-α还原酶的表达与前列腺癌生物学行为相关性研究

Correlation between 5-α reductase and biological behavior of prostate cancer

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	蒋铭心, 苏瑶, 熊天宇, 叶小波, 靳松, 邢念增, 金木兰, 杨敏福, 牛亦农. 减瘤性根治性前列腺切除术对骨转移前列腺癌患者的临床疗效分析[J]. 首都医科大学学报, 2021, 42(6): 967-972.
[2]	王明帅, 熊天宇, 蒋铭心, 钱小松, 王思豪, 崔韵, 牛亦农. 改良前列腺尖部分离技术保留尿道周围结构对前列腺癌根治术后即刻尿控的影响[J]. 首都医科大学学报, 2021, 42(6): 973-977.
[3]	叶小波, 熊天宇, 崔韵, 王明帅, 杨辉, 安卓玲, 牛亦农. 醋酸阿比特龙联合强的松治疗去势抵抗型前列腺癌的疗效分析[J]. 首都医科大学学报, 2021, 42(6): 978-985.
[4]	樊笑琪, 刘志斌, 王明帅, 瓦斯里江·瓦哈甫, 宋黎明, 邢念增, 牛亦农. 腹腔镜单纯尿道前壁加强法与尿道前后壁加强法(Sandwich法)改善前列腺癌根治术后早期尿控的对比分析[J]. 首都医科大学学报, 2020, 41(4): 542-546.
[5]	白志杰, 王新胜, 马洪顺, 李波. mpMRI与超声融合导航技术在前列腺靶向穿刺的临床研究[J]. 首都医科大学学报, 2020, 41(4): 631-635.
[6]	谢英伟, 金仕鹏, 李爽, 王永辉, 王伟, 平浩, 刘跃新. TMPRSS2-ERG融合基因与转移性去势抵抗性前列腺癌化学药物治疗后生存率的关系[J]. 首都医科大学学报, 2020, 41(1): 103-107.
[7]	平浩, 马林祥, 王明帅, 龙军, 牛亦农, 刘跃新, 邢念增. 单羧酸转运蛋白4(MCT4)在前列腺癌中的表达及调控研究[J]. 首都医科大学学报, 2019, 40(1): 59-64.
[8]	王蔚, 苏嘉明, 袁东波, 张伟, 陈卫红, 孙兆林, 朱建国. 微管相关蛋白1A在前列腺癌中的表达与其临床特征的关系[J]. 首都医科大学学报, 2019, 40(1): 65-71.
[9]	谢英伟, 金世鹏, 闫伟, 王伟, 平浩, 刘跃新. TMPRSS2-ERG融合基因在淋巴结转移前列腺癌中的阳性率及与生存的关系[J]. 首都医科大学学报, 2019, 40(1): 72-77.
[10]	左灵坤, 阳荣辉, 马慧, 周萍, 孔璐. 生物信息学方法分析前列腺癌组织及细胞系中LMNA基因第七外显子点突变[J]. 首都医科大学学报, 2017, 38(6): 884-890.
[11]	张继伟, 阎乙夫, 夏溟. 低危前列腺癌¹²⁵I粒子植入治疗尿路合并症的临床分析[J]. 首都医科大学学报, 2017, 38(2): 325-328.
[12]	刘宝东, 支修益. 肺癌第8版TNM分期解读与展望[J]. 首都医科大学学报, 2016, 37(6): 753-757.
[13]	瓦斯里江·瓦哈甫, 牛亦农, 邢念增. 前列腺癌化疗的发展及未来[J]. 首都医科大学学报, 2016, 37(3): 299-306.
[14]	刘志斌, 靳松, 张军晖, 王建文, 田溪泉, 田龙, 牛亦农, 邢念增. 腹腔镜Sandwich法尿道及周围组织重建改善高风险组前列腺癌根治术后早期尿控的研究[J]. 首都医科大学学报, 2016, 37(3): 313-317.
[15]	靳松, 张天, 郑颖洁, 宋黎明, 平浩, 瓦斯里江·瓦哈甫, 牛亦农, 邢念增. 高危组前列腺癌根治术后雄激素剥夺治疗联合早期放射治疗对局部控制及近期生存率的影响[J]. 首都医科大学学报, 2016, 37(3): 318-322.